SeaStar Medical (NASDAQ:ICU) Trading Up 6.7% – Still a Buy?

Shares of SeaStar Medical Holding Corporation (NASDAQ:ICU) traded up 6.7% on Friday . The company traded as high as $0.73 and last traded at $0.71. 1,507,250 shares were traded during trading, a decline of 15% from the average session volume of 1,777,752 shares. The stock had previously closed at $0.66.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded SeaStar Medical from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd.

SeaStar Medical Price Performance

The business has a 50 day moving average of $0.92 and a 200 day moving average of $1.42. The firm has a market capitalization of $7.95 million, a price-to-earnings ratio of -0.20 and a beta of -1.09.

SeaStar Medical (NASDAQ:ICU) last posted its earnings results on Wednesday, May 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.08. The business had revenue of $0.29 million during the quarter, compared to analyst estimates of $0.15 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tyche Wealth Partners LLC bought a new stake in shares of SeaStar Medical in the first quarter valued at about $63,000. Geode Capital Management LLC raised its stake in SeaStar Medical by 14.1% in the fourth quarter. Geode Capital Management LLC now owns 45,430 shares of the company’s stock valued at $88,000 after buying an additional 5,618 shares during the period. Finally, Armistice Capital LLC bought a new stake in SeaStar Medical in the first quarter valued at approximately $1,018,000. 1.69% of the stock is owned by institutional investors and hedge funds.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.